C3 and systemic lupus erythematosus: In a study evaluating SLE patients with secondary non-response to RTX (2NDNR), obinutuzumab was found to be effective and steroid-sparing, with the following key effects: significant reductions in disease activity measured by SLEDAI-2K (SLE Disease Activity Index) and BILAG-2004 (British Isles Lupus Assessment Group) scores, improvement in complement C3 and reduction in anti-dsDNA titers, some patients achieved LLDAS (Lupus Low Disease Activity State), also peripheral B cell depletion was observed.